Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 30, 2009
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
Key Financial Metrics and Transaction Terms
The filing details a Cross License Agreement with International Spinal Innovations, LLC (ISI) rather than standard periodic financial results. Key financial terms include:
- Equity Issuance: 260,000 shares of common stock issued to ISI on June 30, 2009.
- Cash Consideration: Sales milestone payments in cash (specific amounts not disclosed).
- Royalties: Payments based on net sales of licensed products with minimum annual royalties beginning in the second year after the first commercial sale.
- Liquidity/Debt: The filing text does not provide a clear value for current revenue, profit, cash flow, or debt levels.
Material Changes and Agreements
On June 30, 2009, Alphatec Spine, Inc. (a wholly owned subsidiary) entered into a Cross License Agreement with ISI. Material changes include:
- Inbound License: Alphatec Spine received a worldwide license to develop and commercialize ISI's proprietary intellectual property for a stand-alone anterior lumbar interbody fusion device (ALIF Device).
- Outbound License: Alphatec Spine licensed certain of its own ALIF Device technology to ISI.
- Termination Rights: ISI may terminate if Alphatec Spine fails to make a first commercial sale within an allotted time, unless Alphatec Spine delays termination via payment. Alphatec Spine may terminate for convenience with 90 days' notice.
Guidance, Risks, and Contingencies
Regulatory Compliance: The issuance of 260,000 shares was made pursuant to exemptions from registration under Rule 506 of Regulation D and/or Section 4(2) of the Securities Act of 1933. The investor represented an intention to acquire securities for investment only.
Risks and Contingencies:
- Commercialization Risk: The agreement contains a termination clause if the first commercial sale of the licensed product is not made within a specific timeframe.
- Intellectual Property Retention: Upon certain terminations, ISI may retain the intellectual property licensed from Alphatec Spine in exchange for payments.
- Future Obligations: The company faces future cash obligations for milestone payments and minimum annual royalties contingent on commercial sales.
Investor Verification Checklist
- Verify the market value of the 260,000 shares issued to ISI on June 30, 2009, to assess immediate dilution.
- Review the upcoming Form 10-Q for the quarter ended June 30, 2009, for the full text of the License Agreement and specific cash milestone amounts.
- Confirm the specific "allotted time period" for the first commercial sale required to prevent termination by ISI.
- Assess the impact of minimum annual royalties on future cash flow once commercial sales commence.